2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on …
Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
[HTML][HTML] Patients, families, and communities COVID-19 impact assessment: Lessons learned and compelling needs
F Isasi, MD Naylor, D Skorton, DC Grabowski… - NAM …, 2021 - ncbi.nlm.nih.gov
The health system exists to serve the most fundamental need of society: people's health and
well-being. To do so effectively requires engaging people as a partnership proposition in all …
well-being. To do so effectively requires engaging people as a partnership proposition in all …
Race/ethnicity reporting and representation in US clinical trials: a cohort study
BE Turner, JR Steinberg, BT Weeks… - The Lancet Regional …, 2022 - thelancet.com
Background Systemic progress in improving trial representation is uncertain, and previous
analyses of minority trial participation have been limited to small cohorts with limited …
analyses of minority trial participation have been limited to small cohorts with limited …
Increasing Participation of Women in Cardiovascular Trials: JACC Council Perspectives
L Cho, AR Vest, ML O'Donoghue, MO Ogunniyi… - Journal of the American …, 2021 - jacc.org
Although some progress has been made in the last 3 decades to increase the number of
women in clinical cardiology trials, review of recent cardiovascular literature demonstrates …
women in clinical cardiology trials, review of recent cardiovascular literature demonstrates …
Improving representation in clinical trials and research: building research equity for women and underrepresented groups
K Bibbins-Domingo, A Helman - 2022 - pubmed.ncbi.nlm.nih.gov
The United States has long made substantial investments in clinical research with the goal
of improving the health and well-being of our nation. There is no doubt that these …
of improving the health and well-being of our nation. There is no doubt that these …
[HTML][HTML] Improving the enrollment of women and racially/ethnically diverse populations in cardiovascular clinical trials: an ASPC practice statement
Cardiovascular disease (CVD) remains the leading cause of death for both women and men
worldwide. In the United States (US), there are significant disparities in cardiovascular risk …
worldwide. In the United States (US), there are significant disparities in cardiovascular risk …
2022 ACC/AHA/HFSA guideline for the management of heart failure
ABSTRACT Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
The need for increased pragmatism in cardiovascular clinical trials
The majority of cardiovascular randomized controlled trials (RCTs) test interventions in
selected patient populations under explicitly protocol-defined settings. Although these …
selected patient populations under explicitly protocol-defined settings. Although these …
Underrepresentation of women in randomized controlled trials: a systematic review and meta-analysis
V Daitch, A Turjeman, I Poran, N Tau, I Ayalon-Dangur… - Trials, 2022 - Springer
Background Although regulatory changes towards correcting the underrepresentation of
women in randomized controlled trials (RCTs) occurred (National Institutes of Health 1994) …
women in randomized controlled trials (RCTs) occurred (National Institutes of Health 1994) …
[HTML][HTML] Representation of women in heart failure clinical trials: barriers to enrollment and strategies to close the gap
Heart failure is a significant public health burden that differentially impacts women. Important
sex-and gender-based differences in HF risk factors, presentation, and treatment exist, and …
sex-and gender-based differences in HF risk factors, presentation, and treatment exist, and …